Tempo reale stimato
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
1,86 USD | -1,06% |
|
+13,98% | -91,89% |
08/07 | Aerovate Therapeutics esplora alternative strategiche | CI |
08/07 | Aerovate Therapeutics esplorerà alternative strategiche dopo l'interruzione del trial sull'ipertensione | MT |
Attività
Numero di dipendenti: 51
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Benjamin Dake
FOU | Founder | 48 | 27/07/18 |
Timothy Noyes
CEO | Chief Executive Officer | 62 | 01/02/21 |
George Eldridge
DFI | Director of Finance/CFO | 61 | 01/03/21 |
Marco Verwijs
CTO | Chief Tech/Sci/R&D Officer | - | 01/03/22 |
Hunter Gillies
CTO | Chief Tech/Sci/R&D Officer | 58 | 01/05/20 |
Ralph Niven
CTO | Chief Tech/Sci/R&D Officer | 64 | 01/07/20 |
Timothy Pigot
PRN | Corporate Officer/Principal | - | 01/06/21 |
Sue Fischer
PRN | Corporate Officer/Principal | - | - |
Donna Dea
LAW | General Counsel | - | 01/09/20 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Donald Santel
BRD | Director/Board Member | 62 | 19/01/23 |
Maha Katabi
BRD | Director/Board Member | 50 | 01/08/20 |
Timothy Noyes
CEO | Chief Executive Officer | 62 | 01/02/21 |
Dave Grayzel
BRD | Director/Board Member | 56 | 01/08/20 |
Mark Iwicki
BRD | Director/Board Member | 57 | 01/02/21 |
Joshua Resnick
BRD | Director/Board Member | 49 | 01/10/18 |
Allison Dorval
BRD | Director/Board Member | 48 | 15/07/21 |
Habib Dable
CHM | Chairman | 54 | 10/07/23 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 28 808 334 | 28 798 566 ( 99,97 %) | 0 | 99,97 % |
Coordinate società
![Indirizzo Aerovate Therapeutics, Inc.(AVTE)](https://cdn.zonebourse.com/static/address/124268141.png)
Settore
![Consenso](/images/consensus_flch.gif)
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
-91,89% | 54,19 Mln | |
+24,57% | 47,07 Mrd | |
+46,45% | 42,06 Mrd | |
-3,07% | 39,98 Mrd | |
+37,31% | 33,02 Mrd | |
-6,30% | 27,9 Mrd | |
+18,91% | 27,63 Mrd | |
+48,01% | 14,37 Mrd | |
+44,45% | 13,45 Mrd | |
+1,18% | 12,03 Mrd |
- Borsa valori
- Azioni
- Azione AVTE
- Società Aerovate Therapeutics, Inc.